Sihpromatum - I Grew my Boobs in China: Volume 1

Product Information

This study showed improving but still low levels of breast cancer screening coverage of women in China. Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Daiichi Sankyo is responsible for the manufacturing and supply of Enhertu and datopotamab deruxtecan.

This study aimed to provide an update on the current status of breast cancer screening levels in China, estimating the screening rates across subgroups using the latest nationally and provincially representative surveillance data.Nevertheless, screening uptake remained low compared to screening rates of above 50% in developed countries ( 6).

However, most of the data in the reviews, derived from age-based stratified analyses in breast cancer studies.

Previously, patients with HR-positive metastatic breast cancer and HER2-low disease have had limited effective treatment options following progression on endocrine (hormone) therapy. The study was approved by the Ethical Committee of the National Center for Chronic and Non-Communicable Disease Control and Prevention, China CDC.

Health education and accessibility of screening services to women across the country should be strengthened, especially to women aged 50 years and above. Enhertu now has the potential to become a new standard of care treatment option in China for a broad range of patients with HER2-expressing metastatic breast cancer.The study also found that reporting breast screening was less likely among women with the lowest education level (16. Breast binding became an exclusive aesthetic practice for women continuing until the 1930s, with more prevalence among upper-class women. This study found that the group aged 30–49 years had the highest screening rates, whereas the 60 years and above age groups had The proportion of breast cancer under 35 years old in rural areas is growing faster than that in urban areas, which may be related to the change of rural lifestyle and the enhancement of health awareness. Key secondary endpoints include PFS based on BICR in all randomised patients (HR-positive and HR-negative disease), OS in patients with HR-positive disease and OS in all randomised patients (HR-positive and HR-negative disease).